This population-based descriptive study will characterize first-time users of three NOACs (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial fibrillation (SPAF) patients and will assess the patterns of drug utilization in routine general practice in Colombia

Inclusion Criteria:

• First prescription of NOACs (rivaroxaban, dabigatran and apixaban) in the outpatient setting.
• Non valvular Atrial Fibrillation (NVAF) Patients
• aged ≥18 years
• at least one year of enrollment in the Audifarma database
• one year since first encounter with healthcare provider will be included in the study

Exclusion Criteria:

• Patients with any record of index drug prescription prior to the enrolment period.
• Patients who qualify as members of more than one cohort study on the same day

Using the population from the Audifarma database, the study will be comprised of three separate cohorts of first time users of rivaroxaban, dabigatran and apixaban using the first prescription date (index date) of the respective drug (index drug). All patients aged ≥18 years with at least one year of enrollment in the databases and one year since first encounter with healthcare provider will be included in the study.